[Viral Safety of Biologicals]

Overview

Journal Ann Pharm Fr

Specialties Pharmacology
Pharmacy

Date 2008 Aug 19

PMID 18706341

Authors

F Barin

Affiliations

Soon will be listed here.

Abstract

The viral safety of biologicals, either human blood derivatives or animal products or recombinant proteins issued from biotechnology, relies on the quality of the starting material, the manufacturing process and, if necessary, the control of the final product. The quality of the starting material is highly guaranteed for blood derivatives due to the individual screening for specific markers (antigens, genome, antibodies) for major blood borne viruses such as hepatitis B and C viruses (HBV, HCV) and human immunodeficiency virus (HIV). It can be reinforced by the detection through amplification procedures (polymerase chain reaction) in the plasma pool of genomes from viruses that have been implicated in contaminations of blood derivatives in the past (parvovirus B19, hepatitis A virus). The association in the manufacturing process of different steps dedicated to purification of plasma proteins (partitioning), virus inactivation (solvent/detergent treatment, heat inactivation) or specific procedures allowing virus removal (nanofiltration) allows to reduce the viral risk very efficiently. The validation studies using scaled down systems and model viruses allow to evaluate the virus safety of any product quantitatively. The aim of these procedures is to guarantee the lack of infectivity due to any virus, either known or unknown.

References

Yi M, Lemon S . Replication of subgenomic hepatitis A virus RNAs expressing firefly luciferase is enhanced by mutations associated with adaptation of virus to growth in cultured cells. J Virol. 2002; 76(3):1171-80. PMC: 135777. DOI: 10.1128/jvi.76.3.1171-1180.2002. View

Blumel J, Schmidt I, Effenberger W, Seitz H, Willkommen H, Brackmann H . Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion. 2002; 42(11):1473-81. DOI: 10.1046/j.1537-2995.2002.00221.x. View

Delwart E, Kalmin N, Jones T, Ladd D, Foley B, Tobler L . First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang. 2004; 86(3):171-7. DOI: 10.1111/j.0042-9007.2004.00416.x. View

Horaud F . Biologicals: an attempt at classification and its implication for the viral safety of products. Dev Biol Stand. 1993; 81:17-24. View

Najioullah F, Barlet V, Renaudier P, Guitton C, Crova P, Guerin J . Failure and success of HIV tests for the prevention of HIV-1 transmission by blood and tissue donations. J Med Virol. 2004; 73(3):347-9. DOI: 10.1002/jmv.20097. View

Horowitz B, Prince A, HOROWITZ M, Watklevicz C . Viral safety of solvent-detergent treated blood products. Dev Biol Stand. 1993; 81:147-61. View

Santagostino E, Mannucci P, Gringeri A, Azzi A, Morfini M, Musso R . Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion. 1997; 37(5):517-22. DOI: 10.1046/j.1537-2995.1997.37597293884.x. View

Lemon S . Hepatitis A virus and blood products: virus validation studies. Blood Coagul Fibrinolysis. 1995; 6 Suppl 2:S20-2. DOI: 10.1097/00001721-199506002-00005. View

Stramer S, Glynn S, Kleinman S, Strong D, Caglioti S, Wright D . Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med. 2004; 351(8):760-8. DOI: 10.1056/NEJMoa040085. View

10.

Aubin J, Defer C, Vidaud M, Maniez Montreuil M, Flan B . Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang. 2000; 78(1):7-12. DOI: 10.1159/000031142. View

11.

Rouzioux C, Brun-Vezinet F, Courouce A, Gazengel C, VERGOZ D, Desmyter J . Immunoglobulin G antibodies to lymphadenopathy-associated virus in differently treated French and Belgian hemophiliacs. Ann Intern Med. 1985; 102(4):476-9. DOI: 10.7326/0003-4819-102-4-476. View

12.

Peiris J, Yu W, Leung C, Cheung C, Ng W, Nicholls J . Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet. 2004; 363(9409):617-9. PMC: 7112424. DOI: 10.1016/S0140-6736(04)15595-5. View

13.

Kenny-Walsh E . Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999; 340(16):1228-33. DOI: 10.1056/NEJM199904223401602. View

14.

Spillmann D . Heparan sulfate: anchor for viral intruders?. Biochimie. 2001; 83(8):811-7. DOI: 10.1016/s0300-9084(01)01290-1. View

15.

Pillonel J, Laperche S . Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill. 2005; 10(2):5-8. DOI: 10.2807/esm.10.02.00519-en. View

16.

Anderson J, Andreadis T, Vossbrinck C, Tirrell S, Wakem E, French R . Isolation of West Nile virus from mosquitoes, crows, and a Cooper's hawk in Connecticut. Science. 1999; 286(5448):2331-3. DOI: 10.1126/science.286.5448.2331. View

17.

Vabret A . [Emerging infectious diseases and cross-species transmissions]. Virologie (Montrouge). 2021; 10(5):329-332. DOI: 10.1684/vir.2011.6719. View

18.

Brown P, Preece M, Will R . "Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet. 1992; 340(8810):24-7. DOI: 10.1016/0140-6736(92)92431-e. View

19.

Chudy M, Budek I, Keller-Stanislawski B, McCaustland K, Neidhold S, Robertson B . A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol. 1999; 57(2):91-9. DOI: 10.1002/(sici)1096-9071(199902)57:2<91::aid-jmv1>3.0.co;2-l. View

20.

Chua K, Bellini W, Rota P, Harcourt B, Tamin A, Lam S . Nipah virus: a recently emergent deadly paramyxovirus. Science. 2000; 288(5470):1432-5. DOI: 10.1126/science.288.5470.1432. View